Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

Date publication

juin 2015

Journal

The Lancet. Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier

Tous les auteurs :
Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, Dere RC, Lu D, Jones S, Jones C, Chu YW, Morschhauser F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25925619

Résumé

Patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) have an unfavourable prognosis with few treatment options. Polatuzumab vedotin is an antibody-drug conjugate containing an anti-CD79B monoclonal antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E. We aimed to assess the safety and clinical activity of polatuzumab vedotin in relapsed or refractory B-cell NHL and chronic lymphocytic leukaemia (CLL).

Mots clés

Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, administration & dosage, Antibodies, Monoclonal, Murine-Derived, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, CD79 Antigens, biosynthesis, Drug Administration Schedule, Female, Humans, Immunoconjugates, administration & dosage, Leukemia, Lymphocytic, Chronic, B-Cell, drug therapy, Lymphoma, Non-Hodgkin, drug therapy, Male, Middle Aged, Prognosis, Rituximab

Référence

Lancet Oncol.. 2015 Jun;16(6):704-15